Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis

The Journal of Cell Biology(2023)10.1083/jcb.202209114Source: DataRank Database

Matriptase drives dissemination of ovarian cancer spheroids by a PAR-2/PI3K/Akt/MMP9 signaling axis is a research paper published in The Journal of Cell Biology (2023). On theSindex it has a DataRank of 0. It has been cited 37 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access37 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)OA: bronzeTopics (21)Linked Datasets (20)DataCite Reuse (20)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Marguerite S. Buzza ORCID,Nadire Duru ORCID,Amando A. Strong ORCID,Toni Antalis ORCID,Nisha R. Pawar ORCID

Live enrichment

PubMed:37737895 PMC:PMC10515437

National Institutes of Health

Grant: R01CA196988

National Institutes of Health

Grant: R01HL118390

National Institutes of Health

Grant: T32CA154274

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Cancer Center Support Grant

Grant: P30CA134274

Maryland Department of Health’s Cigarette Restitution

Grant: CH-649-CRF

Rivkin Center for Ovarian Cancer

Grant: 30034041/3003404

American Cancer Society

Grant: IRG-18-160-16

Meyerhoff Fellowship

Grant: R25-GM055036

NIGMS NIH HHS

Grant: R25 GM055036

National Institutes of Health

Grant: 5T32CA154274-14

Training Grant in Cancer Biology

National Institutes of Health

Grant: 5R01HL118390-02

Membrane Serine Protease Activities in Protease Activated Receptor Signaling

National Institutes of Health

Grant: 5R25GM055036-23

Expanding Participation by Minorities in Biomedical Sciences

National Institutes of Health

Grant: 2P30CA134274-04

Protocol Specific Research

National Institutes of Health

Grant: 1R01CA196988-01A1

Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer

Maryland Health Care System

bronzeLicense: CC BY NC SA

publisherhttps://rupress.org/jcb/article-pdf/222/11/e202209114/1918699/jcb_202209114.pdf

publisherhttps://rupress.org/jcb/article-pdf/doi/10.1083/jcb.202209114/1918699/jcb_202209114.pdf

Europe_PMChttps://europepmc.org/articles/PMC10515437

Europe_PMChttps://europepmc.org/articles/PMC10515437?pdf=render

https://doi.org/10.1083/jcb.202209114

Fields of Study

0301 basic medicine03 medical and health sciences

MeSH Terms

Spheroids, CellularHumansOvarian NeoplasmsSerine EndopeptidasesSignal TransductionFemaleProto-Oncogene Proteins c-aktMatrix Metalloproteinase 9Phosphatidylinositol 3-Kinases

Keywords

Ovarian NeoplasmsPhosphatidylinositol 3-KinasesMatrix Metalloproteinase 9Spheroids, CellularSerine EndopeptidasesHumansFemaleProto-Oncogene Proteins c-aktArticleSignal Transduction

Additional file 1 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669901.v1figshare

Additional file 1 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669901figshare

Additional file 9 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669925.v1figshare

Additional file 10 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669928figshare

Additional file 9 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669925figshare

Additional file 10 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669928.v1figshare

Additional file 8 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669922figshare

Additional file 6 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669916figshare

Additional file 5 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669913figshare

Additional file 6 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669916.v1figshare

Additional file 7 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669919figshare

Additional file 7 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669919.v1figshare

Additional file 8 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669922.v1figshare

Additional file 2 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669904.v1figshare

Additional file 4 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669910.v1figshare

Additional file 3 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669907figshare

Additional file 3 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669907.v1figshare

Additional file 4 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669910figshare

Additional file 5 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669913.v1figshare

Additional file 2 of CircNUP50 is a novel therapeutic target that promotes cisplatin resistance in ovarian cancer by modulating p53 ubiquitination

10.6084/m9.figshare.26669904figshare